Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05564481
Other study ID # Pro00016314
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 1, 2022
Est. completion date December 30, 2026

Study information

Verified date February 2024
Source Children's National Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Consistent use of continuous glucose monitors (CGM) has the potential to improve glycemic control and related type 1 diabetes (T1D) health outcomes, however young adolescents with T1D are the least likely age group to begin and sustain use of CGM. The proposed study will conduct a feasibility trial of a behavioral intervention designed to optimize use of CGM in adolescents specifically targeting underrepresented populations in diabetes technology research.


Description:

Young adolescents (ages 10-15) with type 1 diabetes (T1D) are at high risk for deterioration of glycemic control and relatedly poor overall T1D self-management. Continuous glucose monitors (CGM) provide real-time indicators of glucose levels and alert users to hypoglycemia and hyperglycemia. Consistent, informed use of CGM has the potential to improve glycemic control and related T1D health outcomes. However, adolescents with T1D are the least likely age group to utilize CGM and significant health disparities exist in access to and use of CGM among youth from racial and ethnic minority backgrounds and youth with public insurance. Adolescent CGM users also continue to evidence A1c levels above recommended targets, potentially due challenges related to perceived CGM burden and related family functioning. Novel, developmentally targeted interventions delivered early in adolescence could promote optimal uptake and use of CGM and reduce psychosocial barriers to sustained use but must be evaluated in rigorous pilot trials that attend to health disparities. The current study proposes to evaluate an innovative behavioral intervention that utilizes certified diabetes care and education specialists (CDCES) to teach problem-solving and communication skills around CGM data and use, targeting adolescent-parent T1D interactions related to glucose data, individualized CGM challenges, and weekly adolescent-parent joint review of CGM reports. The intervention also addresses HCP knowledge of health disparities in diabetes technology through interactive education, and boosts family support through connection with peer parent consultants. This study aims to evaluate the preliminary efficacy of the behavioral intervention to enhance CGM use and resulting T1D health outcomes. Sixty adolescents and their parents will be recruited for this pilot randomized trial, randomly assigned to either an immediate intervention group or a delayed intervention group serving as a standard care comparison. Intervention content will be delivered via 3 telemedicine sessions with adolescents and a parent and supported by connection with a peer parent consultant. Medical and psychosocial data (including A1c, CGM indicators, CGM burdens and benefits, diabetes distress, and diabetes-related family conflict) will be collected from adolescents and a parent at baseline and three follow-up time points across the first year after CGM initiation. The investigators will employ quantitative and qualitative analyses to evaluate intervention feasibility, acceptability, and impact. Enhancing CGM access and use at this key developmental juncture provides an excellent opportunity for tailored support and problem-solving, resulting in potentially lasting improvement in diabetes self-management. Results of this pilot trial will directly inform a multi-site randomized clinical trial to evaluate efficacy, with the long term goal of identifying effective behavioral strategies that can be integrated into routine diabetes education and care.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 60
Est. completion date December 30, 2026
Est. primary completion date July 1, 2026
Accepts healthy volunteers No
Gender All
Age group 10 Years to 15 Years
Eligibility Inclusion Criteria: - 10-15 years old - Type 1 diabetes - Type 1 diabetes diagnosis = 6 months \ - Starting a continuous glucose monitor for the first time or restarting after = 1 year Exclusion Criteria: - Younger than 10, older than 15 - Diagnosed less than 6 months - Already using CGM or has used within last year - Other major medical condition such as cancer, cystic fibrosis

Study Design


Intervention

Behavioral:
diabetes education and parent coaching support
Intervention sessions will include parent/child discussion about barriers to CGM use, review of CGM data, problem solving, and working as a team.

Locations

Country Name City State
United States Children's National Research Institute Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Children's National Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Glycemic control hemoglobin A1c (HbA1c) Baseline
Primary Glycemic control hemoglobin A1c (HbA1c) 3 months post randomization
Primary Glycemic control hemoglobin A1c (HbA1c) 6 months post randomization
Primary Glycemic control hemoglobin A1c (HbA1c) 12 months post randomization
Primary glycemic variability Using 14-30 days of CGM data Baseline
Primary glycemic variability Using 14-30 days of CGM data 3 months post randomization
Primary glycemic variability Using 14-30 days of CGM data 6 months post randomization
Primary glycemic variability Using 14-30 days of CGM data 12 months post randomization
Secondary Family Conflict The Diabetes Family Conflict Scale-Revised Scored 19-57 where a higher score indicates higher family conflict Baseline
Secondary Family Conflict The Diabetes Family Conflict Scale-Revised Scored 19-57 where a higher score indicates higher family conflict 3 months post randomization
Secondary Family Conflict The Diabetes Family Conflict Scale-Revised Scored 19-57 where a higher score indicates higher family conflict 6 months post randomization
Secondary Family Conflict The Diabetes Family Conflict Scale-Revised Scored 19-57 where a higher score indicates higher family conflict 12 months post randomization
Secondary Diabetes Distress Problem Areas in Diabetes scales (PAID) Scored 14-84 where higher scores indicate higher distress Baseline
Secondary Diabetes Distress Problem Areas in Diabetes scales (PAID) Scored 14-84 where higher scores indicate higher distress 3 months post randomization
Secondary Diabetes Distress Problem Areas in Diabetes scales (PAID) Scored 14-84 where higher scores indicate higher distress 6 months post randomization
Secondary Diabetes Distress Problem Areas in Diabetes scales (PAID) Scored 14-84 where higher scores indicate higher distress 12 months post randomization
Secondary CGM benefits and burdens Continuous glucose monitoring (CGM) Burdens and Benefits as assessed by The BenCGM and BurCGM Baseline
Secondary CGM benefits and burdens Continuous glucose monitoring (CGM) Burdens and Benefits as assessed by The BenCGM and BurCGM 3 months post randomization
Secondary CGM benefits and burdens Continuous glucose monitoring (CGM) Burdens and Benefits as assessed by The BenCGM and BurCGM 6 months post randomization
Secondary CGM benefits and burdens Continuous glucose monitoring (CGM) Burdens and Benefits as assessed by The BenCGM and BurCGM 12 month post randomization
Secondary CGM use Indicators of CGM use, including mean days work per week, will be evaluated to measure sustained use of CGM. Baseline
Secondary CGM use Indicators of CGM use, including mean days work per week, will be evaluated to measure sustained use of CGM. 3 months post randomization
Secondary CGM use Indicators of CGM use, including mean days work per week, will be evaluated to measure sustained use of CGM. 6 months post randomization
Secondary CGM use Indicators of CGM use, including mean days work per week, will be evaluated to measure sustained use of CGM. 12 months post randomization
Secondary Diabetes self-management The Diabetes Management Questionnaire (DMQ)-a self- and parent-report measure assessing the frequency of engagement in diabetes care behaviors (e.g. BG monitoring, adjusting behavior to specific situations) over the past month.
Scored 0-100 with higher scores indicating higher adherence to diabetes management
Baseline
Secondary Diabetes self-management The Diabetes Management Questionnaire (DMQ)-a self- and parent-report measure assessing the frequency of engagement in diabetes care behaviors (e.g. BG monitoring, adjusting behavior to specific situations) over the past month.
Scored 0-100 with higher scores indicating higher adherence to diabetes management
3 months post randomization
Secondary Diabetes self-management The Diabetes Management Questionnaire (DMQ)-a self- and parent-report measure assessing the frequency of engagement in diabetes care behaviors (e.g. BG monitoring, adjusting behavior to specific situations) over the past month.
Scored 0-100 with higher scores indicating higher adherence to diabetes management
6 months post randomization
Secondary Diabetes self-management The Diabetes Management Questionnaire (DMQ)-a self- and parent-report measure assessing the frequency of engagement in diabetes care behaviors (e.g. BG monitoring, adjusting behavior to specific situations) over the past month.
Scored 0-100 with higher scores indicating higher adherence to diabetes management
12 months post randomization
See also
  Status Clinical Trial Phase
Recruiting NCT05653518 - Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes N/A
Enrolling by invitation NCT05515939 - Evaluating the InPen in Pediatric Type 1 Diabetes
Completed NCT05109520 - Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Recruiting NCT04016987 - Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes N/A
Active, not recruiting NCT04190368 - Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes N/A
Recruiting NCT05413005 - Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus Early Phase 1
Active, not recruiting NCT04668612 - Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes N/A
Completed NCT02837094 - Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 Phase 1
Recruiting NCT05414409 - The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action Phase 2
Recruiting NCT05670366 - The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes N/A
Active, not recruiting NCT05418699 - Real-life Data From Diabetic Patients on Closed-loop Pumps
Completed NCT04084171 - Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6 N/A
Recruiting NCT06144554 - Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
Recruiting NCT05153070 - Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes Phase 2
Recruiting NCT05379686 - Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes N/A
Completed NCT05281614 - Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D Early Phase 1
Withdrawn NCT04259775 - Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes N/A
Active, not recruiting NCT01600924 - Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
Completed NCT02750527 - Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
Completed NCT02855307 - Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes Phase 2